Ledger. Australian venture funding, tracked

Chief Executive Officer, Pathios Therapeutics

Paul G. Higham

Coverage

Stories naming Paul G. Higham. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Funding announcement

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers

Pathios Therapeutics has begun treating patients in an Australian Phase 1/2 trial of its GPR65 inhibitor PTT-4256 for advanced solid tumours. Backers to date include Canaan, Brandon Capital and Bristol Myers Squibb.

Brandon BioCatalyst portfolio 21 Nov 2024 Brandon CapitalBristol-Myers SquibbCanaanGrey Wolf TherapeuticsM:M Bio Pty LtdPathios TherapeuticsThirtyFiveBioVida Strategic PartnersPaul G. HighamTim BronsDr Tom McCarthy
Funding announcement

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers

Pathios Therapeutics has dosed the first patient in a Phase 1/2 trial of its GPR65 inhibitor PTT-4256, run by its Australian team; the company also cites US$58M raised to date.

Brandon Capital portfolio 21 Nov 2024 Brandon CapitalBristol-Myers SquibbCanaanGrey Wolf TherapeuticsM:M Bio Pty LtdMolecule to Medicine (MTM)Pathios TherapeuticsThirtyFiveBioVida Strategic PartnersPaul G. HighamTim BronsDr Tom McCarthy

Something wrong? Tell us